Pharvaris (PHVS) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T17:52:52.084Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:52:52.084Z.

Quote observation: 2026-10-06T17:50:14.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -211,936,009.74255
Quote market capitalization: 2,166,970,303
Total debt · period ending 2026-06-30: 769,518.64704
Cash · period ending 2026-06-30: 363,535,334.76

FMP input reference: 2e72a758e634708c28c06ae15f1e09243225437df43ff658102191b35b06d910

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

PHVS EBITDA Yield Metrics

EBITDA YIELD

N/A

PHVS Competitors' EBITDA Yield

PHVS

Pharvaris N.V.

Current

Market Cap

$2.17B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLS

SELLAS Life Sciences Group, Inc.

vs PHVS

Market Cap

$2.11B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ADUS

Addus HomeCare Corporation

vs PHVS

Market Cap

$2.11B

EBITDA Yield

7.79%

TTM Avg

7.38%

3Y Avg

6.36%

5Y Avg

5.86%

VERA

Vera Therapeutics, Inc.

vs PHVS

Market Cap

$2.08B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VCEL

Vericel Corporation

vs PHVS

Market Cap

$2.07B

EBITDA Yield

1.52%

TTM Avg

1.16%

3Y Avg

0.60%

5Y Avg

0.56%

CLDX

Celldex Therapeutics, Inc.

vs PHVS

Market Cap

$2.06B

EBITDA Yield

N/A

TTM Avg

1.31%

3Y Avg

2.16%

5Y Avg

2.16%

ALVO

Alvotech

vs PHVS

Market Cap

$2.06B

EBITDA Yield

2.40%

TTM Avg

3.21%

3Y Avg

2.55%

5Y Avg

2.55%

VRDN

Viridian Therapeutics, Inc.

vs PHVS

Market Cap

$2.06B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRMY

Harmony Biosciences Holdings, Inc.

vs PHVS

Market Cap

$2.28B

EBITDA Yield

13.59%

TTM Avg

15.75%

3Y Avg

13.75%

5Y Avg

10.29%

MRVI

Maravai LifeSciences Holdings, Inc.

vs PHVS

Market Cap

$2.29B

EBITDA Yield

6.32%

TTM Avg

11.96%

3Y Avg

10.61%

5Y Avg

16.98%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Pharvaris N.V. (PHVS)	$2.17B	N/A	N/A	N/A	N/A
SELLAS Life Sciences Group, Inc. (SLS)vs ›	$2.11B	N/A	N/A	N/A	N/A
Addus HomeCare Corporation (ADUS)vs ›	$2.11B	7.79%	7.38%	6.36%	5.86%
Vera Therapeutics, Inc. (VERA)vs ›	$2.08B	N/A	N/A	N/A	N/A
Vericel Corporation (VCEL)vs ›	$2.07B	1.52%	1.16%	0.60%	0.56%
Celldex Therapeutics, Inc. (CLDX)vs ›	$2.06B	N/A	1.31%	2.16%	2.16%
Alvotech (ALVO)vs ›	$2.06B	2.40%	3.21%	2.55%	2.55%
Viridian Therapeutics, Inc. (VRDN)vs ›	$2.06B	N/A	N/A	N/A	N/A
Harmony Biosciences Holdings, Inc. (HRMY)vs ›	$2.28B	13.59%	15.75%	13.75%	10.29%
Maravai LifeSciences Holdings, Inc. (MRVI)vs ›	$2.29B	6.32%	11.96%	10.61%	16.98%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

PHVS EBITDA Yield Metrics

PHVS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics